BOEHRINGER-INGELHEIM: Refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials
Boehringer Ingelheim announced that their Phase II Alzheimer’s disease trials with investigational compound BI 409306 had not met their efficacy endpoints and plans for further trials with BI 409306 in AD will therefore not be pursued. Read More »